May 31, 2024- B. Braun Medical Inc. announced the launch of its new Levetiracetam in Sodium Chloride Injection line of products. This new product offering expands the company’s portfolio in the anticonvulsant space with Levetiracetam in three concentrations. Levetiracetam in Sodium Chloride Injection, manufactured by B. Braun in Irvine, CA, is available in our flexible PAB® IV Containers in 500 mg/100 mL, 1,000 mg/100 mL and 1,500 mg/100 mL strengths.
Making the PAB IV Containers in Irvine helps ensure B. Braun’s supply reliability. This Levetiracetam product offering includes features such as stackable, biodegradable individual unit inner cartons, unique colors for dosage differentiation and an 18-month shelf life. In addition, the inner cartons fit compactly around the containers to minimize wasted space.
Levetiracetam in Sodium Chloride Injection is indicated for adjunct therapy in adults who are 16 years old or older with the following seizure types when oral administration is temporarily not feasible:
- Partial-onset seizures
- Myoclonic seizures in patients with juvenile myoclonic epilepsy
- Primary generalized tonic-clonic seizures